Trial reportRespiratory medicine2025
A mHealth app for sarcoidosis-associated fatigue: a feasibility randomized control trial.
Trial report in Respiratory medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Advances in management of sarcoidosis-associated fatigue: A narrative review.Sarcoidosis, vasculitis, and diffuse lung diseases : official journal of WASOG · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
backgroundSarcoidosis associated fatigue (SAF) is the most reported symptom by sarcoidosis patients and leads to impaired quality of life (QOL). It is strongly associated with stress and negative mood states, and accessible and effective treatments are lacking. mHealth has emerged as a viable platform for QOL self-management interventions. We sought to evaluate the feasibility and preliminary efficacy of a mHealth App, the Sarcoidosis Patient Assessment and Resource Companion (SPARC) App, to improve SAF.
methodsPatients with a fatigue assessment scale (FAS) score ≥22 were randomized to either standard of care or the SPARC App which included modules containing educational videos and breathing awareness meditation (BAM). After completing the education modules, patients were instructed to use the BAM module daily for three months. Primary outcomes of usability and feasibility were assessed at three and six months.
resultsBaseline fatigue and stress scores were similarly elevated in the 49 randomized patients. While usability scores were generally favorable (uMARS functionality 3.7, engagement 3.1), only 40 % of patients in the SPARC group met the pre-defined criteria for adherence. We explored potential sociodemographic influences and key informant interviews provided insight into facilitators/barriers to app use. Fatigue, stress, and QOL scores improved in the SPARC group compared to controls, with a dose-response relationship observed in adherent versus nonadherent patients.
conclusionsOur data suggest mHealth apps may be effective in reducing fatigue and stress and improving QOL in people with sarcoidosis, but deployment of mHealth tools still faces barriers.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.